Toggle Summary
|
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan
|
View HTML
|
Toggle Summary
|
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss
|
View HTML
|
Toggle Summary
|
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to Proceed with Phase II Portion of the OVATION 2 Study After All Phase I Patients Have Completed Their Full Treatment Regimen (up to
|
View HTML
|
Toggle Summary
|
Celsion CEO Issues Letter to Stockholders
LAWRENCEVILLE, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno , the company’s chairman, president and chief executive officer, issued the following letter to stockholders.
|
View HTML
|
Toggle Summary
|
Celsion Corporation Prices $4.8 Million Registered Direct Offering
LAWRENCEVILLE, NJ , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par
|
View HTML
|
Toggle Summary
|
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring
|
View HTML
|
Toggle Summary
|
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that Prof.
|
View HTML
|
Toggle Summary
|
Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia
Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou , China’s biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox ® . Agreement includes numerous financial and non-financial incentives including grants
|
View HTML
|
Toggle Summary
|
Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones for the Phase III OPTIMA Study and the Phase I/II OVATION 2 Study LAWRENCEVILLE,
|
View HTML
|
Toggle Summary
|
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy Analysis Independent Data Safety Monitoring Board (DSMB) Unanimously Recommends Continuation of Phase I Portion of OVATION 2 Study Strong Balance Sheet
|
View HTML
|